Compile Data Set for Download or QSAR
Report error Found 172 Enz. Inhib. hit(s) with all data for entry = 11422
TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM613990(US11744824, Example 3)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM613992(US11744824, Example 5)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM613992(US11744824, Example 5)
Affinity DataIC50: 100nMAssay Description:ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl2), bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM613998(US11744824, Example 11)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM613999(US11744824, Example 12)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614001(US11744824, Example 14)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614002(US11744824, Example 15)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614019(US11744824, Example 32)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614027(US11744824, Example 40)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614027(US11744824, Example 40)
Affinity DataIC50: 100nMAssay Description:ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl2), bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614028(US11744824, Example 41)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614031(US11744824, Example 44)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614037(US11744824, Example 50)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614038(US11744824, Example 51)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614038(US11744824, Example 51)
Affinity DataIC50: 100nMAssay Description:ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl2), bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614044(US11744824, Example 57)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614044(US11744824, Example 57)
Affinity DataIC50: 100nMAssay Description:ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl2), bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614045(US11744824, Example 58)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614046(US11744824, Example 59)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614047(US11744824, Example 60)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614050(US11744824, Example 63)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614051(US11744824, Example 64)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614054(US11744824, Example 67)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614055(US11744824, Example 68)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614056(US11744824, Example 69)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614060(US11744824, Example 73)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614061(US11744824, Example 74)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614062(US11744824, Example 75)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614063(US11744824, Example 76)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614065(US11744824, Example 78)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614066(US11744824, Example 79)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614067(US11744824, Example 80)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614068(US11744824, Example 81)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614069(US11744824, Example 82)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614070(US11744824, Example 83)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614071(US11744824, Example 84)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614072(US11744824, Example 85)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614073(US11744824, Example 86)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614076(US11744824, Example 89)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614076(US11744824, Example 89)
Affinity DataIC50: 100nMAssay Description:ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl2), bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614077(US11744824, Example 90)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614081(US11744824, Example 94)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614082(US11744824, Example 95)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614084(US11744824, Example 97)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614087(US11744824, Example 100)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614088(US11744824, Example 101)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614089(US11744824, Example 102)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614091(US11744824, Example 104)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetTyrosine-protein kinase ABL1(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614091(US11744824, Example 104)
Affinity DataIC50: 100nMAssay Description:ADP-Glo assay kit was purchased from Promega. Magnesium chloride (MgCl2), bovine serum albumin (BSA), ethylene glycol-bis(β-aminoethyl ether)-N,...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

TargetReceptor-interacting serine/threonine-protein kinase 2(Human)
1St Biotherapeutics

US Patent
LigandPNGBDBM614092(US11744824, Example 105)
Affinity DataIC50: 100nMAssay Description:GST-tagged recombinant human RIP2 (25 ng) is incubated with 5 μL of compounds (0.5% DMSO), 5 μL of MBP (0.5 μg/μl) and 5 μL ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/6/2023
Entry Details
Go to US Patent

Displayed 1 to 50 (of 172 total ) | Next | Last >>
Jump to: